CHILDREN’S Cancer Institute
and Sydney Children’s Hospital,
Randwick have announced a
major, new international clinical
trial designed to help combat
neuroblastoma, the most common
solid tumour to affect infants and
young children today.
The trial announcement coincided
with International Childhood
Cancer Awareness month and
offered a new treatment for
children diagnosed with relapsed
neuroblastoma in the form of
difluoromethylornithine (DFMO),
previously used for treating African
Sleeping Sickness, the Children’s
Cancer Institute said.The above article was sent to subscribers in Pharmacy Daily's issue from 02 Sep 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 02 Sep 14
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.